Kurma Partners’ Post

🌟 Summer 2024 Startup Trends 🌟 The biotech sector, especially AI-driven drug discovery, is attracting significant investment. Genesis Therapeutics recently raised $200M, highlighting the growing interest in this innovative field. Stay informed and leverage these trends for your startup's success. #StartupTrends #Biotech #AI #Innovation #Carbon3Recruiting #BusinessGrowth #Entrepreneurship

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/drE4thXY Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dMu5TpiV Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

🧬🚀 Announced at the beginning of January was the "NextGen Class of 2024: Top Life Sciences Start-ups to Watch This Year" article from BioSpace. 🌐🔬 The list is determined by companies based in the US that launched between September 2022 - 2023 with Series A financing. This exciting list comprises 30 organisations that are ones to watch this year! The top 5 include: Rapport Therapeutics - launched in March 2023. Apogee Therapeutics - launched in December 2022. CARGO Therapeutics - launched in March 2023. Aera Therapeutics - launched in February 2023. Nido Biosciences - launched in May 2023. This impressive list can be found in the article linked in the comments. Excited to see what 2024 holds for these companies! #lifesciences #startups #biotech #2024

Why biotech spinouts are in the North East’s genes. 🔎🇬🇧 Ten years ago, I slipped in through a side door to the office block that rings Times Square in Newcastle, next to the Life Science Centre near the city’s central station, and spoke to Jonathan O’Halloran, the co-founder and chief scientific officer of QuantuMDx, a Newcastle-based biotech startup. I was there to write a story on QuantuMDx’s killer product, a Star Trek-like tricorder that would take blood or saliva samples and provide instantaneous results to diagnostic tests. The Q-POC, as it was called, was a revolutionary technology. ➡️ https://lnkd.in/esZE9i6K 🔗 #biotech #startup #spinouts #technology #northeast #genes #UKtech

Can John Maraganore's 'Next-Generation RNAi' Startup Revolutionize Biotech?" Biotech industry veteran, @JMaraganore is back on the scene with a new venture that promises to redefine RNA interference (RNAi). Armed with an impressive $135m in initial funding, Maraganore intends to build on the success of his previous endeavor and push forward into uncharted territories of biotech innovation. What could this mean for disease prevention and treatment? And how might such advancements influence the broader scientific community? Read up on it here 👉 https://lnkd.in/dpN9rQ9x Ignite Corporate Innovation! 🚀 From AI solutions to automation, we provide technical prowess that drives growth. Book your meeting now: https://lnkd.in/dbQkg2ac Join +160k corporate decision-makers, investors & innovative founders. Enhance operations & create new revenue streams through collaboration and startup access. Transcend your innovation strategies into successful ventures! #RNAinterference #Biotechnology #JohnMaraganore #Startup #InnovationStrategy #CorporateInnovation #AIforGrowth #InvestorsCommunity #DiseasePrevention #NextGenTherapeutics

🔬 Lab-testing startups are gearing up for changes as the FDA rolls out new regulations. While the ruling may hike up development costs, there’s optimism among some entrepreneurs and investors. As highlighted by Brian Gormley, this shift could impact financing opportunities, narrowing the pool of venture capitalists willing to invest. Oriana Papin-Zoghbi, co-founder of PrognomiQ, acknowledges the challenges, particularly in the diagnostics market, where securing venture capital can be tough due to limited focus from investment firms. https://lnkd.in/etiEd4nB

The expression “Last but not Least” was never more true than when the startups in PharmStars' current cohort were joined last week by Mark T. Rutledge, PhD of Sumitomo Pharma America, Inc. (SMPA) for the final Fireside Chat of our Spring semester. Mark visited our PharmaU program to engage our startups in a discussion about opportunities for digital health innovation at SMPA. At SMPA (as with many pharma), the landscape for digital health innovation continues to evolve. Mark helped the startups understand how both internal and external forces are influencing change and the impact change is having on SMPA's appetite for innovation. Though market conditions are dictating the need for heightened scrutiny on projects, Mark emphasized SMPA’s continues to focus on opportunities that will deliver value, save money, and help get therapies to the market quickly and to the patients who will benefit from them. SMPA is currently developing their promising oncology assets, which is a perfect fit with PharmStars' current cohort of startups focused on "Digital Innovations in Oncology." We are excited for Mark and his colleagues to meet our startups next month at our culminating Showcase Event where they will share their innovations with SMPA and our other pharma members. Thanks, Mark, for sharing your insights, wisdom and enthusiasm with our Spring cohort of startups. We value your time and your partnership! #Startup #Accelerator #DigitalHealth #pharma #biopharma #innovation #acceleratorprogram #biopharma

#fundingalert 💼Company: En Carta Diagnostics 💰Funding: €1.5 Million ⚡Round: Pre-Seed 👥Investors: CentraleSupélec Venture Diagnostics that enhance patient care, regardless of location. En Carta Diagnostics is a synthetic-biology biotech company that employs patented #technologies to decentralise highly dependable molecular diagnostic solutions. The proceeds will be utilised by En Carta to create a diagnostic device that is capable of independently detecting Lyme disease within minutes. Additionally, the funding will facilitate the #development of a robust ecosystem and the execution of its go-to-market strategy. Guillaume Horréard, Cédric Curtil, Margot Karlikow, PhD Read more - https://lnkd.in/g75Khj7x To share your startup story write us on - contact@startuprise.co.uk #EnCartaDiagnostics #moleculardiagnostic #biotechcompany #funding #fundingnews #startup #startupnews #startuprise